Vaccinex, Inc. Announces $1.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
The registered direct offering and concurrent private placement are referred to herein as the “Transactions.”
- The registered direct offering and concurrent private placement are referred to herein as the “Transactions.”
The closing of the Transactions is expected to occur on or about March 28, 2024, subject to the satisfaction of customary closing conditions. - The gross proceeds from the Transactions are expected to be approximately $1.5 million, before deducting financial advisory fees and other estimated expenses related to the Transactions.
- The Company intends to use the net proceeds from the Transactions for working capital and general corporate purposes.
- A prospectus supplement describing the terms of the registered direct offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov.